Linked Life Data

15663331

Source:http://linkedlifedata.com/resource/pubmed/id/15663331

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-1-24
pubmed:abstractText
ImmunoGen is developing cantuzumab mertansine, in which the CanAg antigen-targeted humanized antibody C242 is conjugated to the company's proprietary cytotoxic agent, DM1, using ImmunoGen's tumor-activated prodrug technology. Cantuzumab mertansine is undergoing phase II trials for the potential treatment of CanAg-expressing cancers, including pancreatic and colorectal cancers and non-small-cell lung cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1464-8431
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
666-74
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Technology evaluation: cantuzumab mertansine, ImmunoGen.
pubmed:affiliation
Australian Nuclear Science and Technology Organisation, Materials Engineering and Science, Menai, NSW 2234. svs@ansto.gov.au
pubmed:publicationType
Journal Article, Review